Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  2010-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.28.15_SUPPL.7500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights

  2017cites this paper
• Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer.

  2017cites this paper
• Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo

  2017cites this paper
• Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models

  2016cites this paper
• Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

  2015cites this paper
• Lung cancer: Biology and treatment options.

  2015cites this paper
• New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material

  2015cites this paper
• Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies

  2014cites this paper
• NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer

  2014cites this paper
• Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor

  2014cites this paper
• Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

  2014cites this paper
• Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?

  2014cites this paper
• Diabetes mellitus as a prognostic factor in advanced non-small-cell lung cancer. To be or not to be: that is as yet an unsolved question.

  2014cites this paper
• A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

  2014cites this paper
• Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

  2014cites this paper
• Tumour Targeting using Radiolabelled Affibody Molecules : Influence of Labelling Chemistry

  2014cites this paper
• Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells

  2014cites this paper
• Emerging combination therapies to overcome resistance in EGFR-driven tumors

  2014cites this paper
• Therapeutic antibodies in breast cancer.

  2014cites this paper
• Antibodies in Cancer Treatment: Early Clinical Development

  2014cites this paper
• The adverse events profile of anti‐IGF‐1R monoclonal antibodies in cancer therapy

  2014cites this paper
• Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy

  2014cites this paper
• Diabetes mellitus as a prognostic factor in advanced non-small-cell lung cancer. To be or not to be: that is as yet an unsolved question.

  2014cites this paper
• Mechanisms of obesity-induced gastrointestinal neoplasia.

  2014cites this paper
• Identification of driver mutations in lung cancer: first step in personalized cancer

  2013cites this paper
• Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors.

  2013cites this paper
• Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

  2013cites this paper
• IGF-1R inhibition: right direction, wrong pathway?

  2013cites this paper
• Tailored management of advanced squamous non-small cell lung cancer (NSCLC)

  2013cites this paper
• Personalized therapy on the horizon for squamous cell carcinoma of the lung.

  2013cites this paper
• Prerequisite Genetic Traits for Metastasis

  2013cites this paper
• A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal

  2013cites this paper
• Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

  2013cites this paper
• Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

  2013cites this paper
• Understanding, recognizing, and managing toxicities of targeted anticancer therapies

  2013cites this paper
• Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

  2013cites this paper
• Treating Breast Cancer in the 21st Century: Emerging Biological Therapies

  2013cites this paper
• Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

  2013cites this paper
• Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin‐Like Growth Factor 1 Receptor, in Healthy Participants

  2013cites this paper
• A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

  2013cites this paper
• Modulation of Insulin-Like Growth Factor-1 Receptor and its Signaling Network for the Treatment of Cancer: Current Status and Future Perspectives

  2013cites this paper
• Metabolic syndrome and cancer: from bedside to bench and back.

  2013cites this paper
• IGF System in Cancer IGF System and Cancer Risk

  2013cites this paper
• Clinical significance of IGF1R expression in non-small-cell lung cancer.

  2012cites this paper
• Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

  2012cites this paper
• Targeting the insulin growth factor receptor 1.

  2012cites this paper
• Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.

  2012cites this paper
• New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

  2012cites this paper
• Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

  2012cites this paper
• Targeting insulin-like growth factor in breast cancer therapeutics.

  2012cites this paper
• Targeted therapy of non-small-cell lung carcinoma

  2012cites this paper
• Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.

  2012cites this paper
• Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

  2012cites this paper
• Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

  2012cites this paper
• Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

  2012cites this paper
• Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

  2012cites this paper
• Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer

  2012cites this paper
• Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

  2012cites this paper
• Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody

  2012influential citation
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cites this paper
• A Novel Classification of Lung Cancer into Molecular Subtypes

  2012cites this paper
• Inhibition of insulin-like growth factor receptor: end of a targeted therapy?

  2012cites this paper
• Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung.

  2012cites this paper
• The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

  2012cites this paper
• Insulin-like growth factor: current concepts and new developments in cancer therapy.

  2012cites this paper
• Favorable outcome associated with an IGF-1 ligand signature in breast cancer

  2012cites this paper
• Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.

  2012cites this paper
• Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells.

  2012cites this paper
• Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.

  2012cites this paper
• Targeting the Insulin-Like Growth Factor-I Receptor in Cancer Therapy

  2012cites this paper
• Development of Targeted Agents and Companion Diagnostics

  2012cites this paper
• The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.

  2012cites this paper
• The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology

  2012cites this paper
• Antikörper zur adoptiven Immuntherapie solider Tumoren

  2012cites this paper
• A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

  2012cites this paper
• Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.

  2012cites this paper
• Tumor control versus adverse events with targeted anticancer therapies

  2012cites this paper
• A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

  2012cites this paper
• Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

  2012cites this paper
• Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

  2012cites this paper
• Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?

  2012cites this paper
• The insulin-like growth factor system in cancer.

  2012cites this paper
• Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines

  2012cites this paper
• Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.

  2011cites this paper
• Target Therapies in Lung Cancer

  2011cites this paper
• Targeting IGF-1R: throwing out the baby with the bathwater?

  2011cites this paper
• Cancer Therapy : Clinical A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab ( MK-0646 ) , an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody , in Patients with Advanced Solid Tumors

  2011cites this paper
• Lung cancer management in 2010.

  2011cites this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cites this paper
• Promising targets and drugs in development for colorectal cancer.

  2011cites this paper
• A role for IGF-1R-targeted therapies in small-cell lung cancer?

  2011cites this paper
• Emerging pathways and future targets for the molecular therapy of pancreatic cancer

  2011cites this paper
• Lung cancer: New biological insights and recent therapeutic advances

  2011cites this paper
• Proteomics and biomarkers in clinical trials for drug development.

  2011cites this paper
• Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

  2011cites this paper
• Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

  2011cites this paper
• An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)

  2011cites this paper
• Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer

  2011cites this paper
• Chemotherapy for Non-Small-Cell Lung Carcinoma: From a Blanket Approach to Individual Therapy

  2011cites this paper
• Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.

  2011cites this paper